Compare OABI & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OABI | CYRX |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | 89 | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.4M | 419.3M |
| IPO Year | N/A | 2008 |
| Metric | OABI | CYRX |
|---|---|---|
| Price | $2.32 | $15.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.50 | ★ $13.31 |
| AVG Volume (30 Days) | 562.9K | ★ 792.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | $52.42 | $11.06 |
| Revenue Next Year | $64.69 | $8.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.32 | $6.69 |
| 52 Week High | $2.79 | $16.73 |
| Indicator | OABI | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 50.93 |
| Support Level | $1.75 | $14.29 |
| Resistance Level | $2.70 | $16.73 |
| Average True Range (ATR) | 0.19 | 0.68 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 54.91 | 29.61 |
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.